All peptides discussed on this page are research compounds supplied for laboratory and scientific investigation under Research Use Only (RUO) conditions. They are not approved medicines, are not intended for human administration, and are not sold for therapeutic, diagnostic or veterinary purposes. Information presented here reflects preclinical research literature and does not constitute medical advice.
Introduction: The Biological Challenge of Stroke Recovery Research
Stroke is the second leading cause of death globally and the leading cause of acquired disability in adults. Ischaemic stroke (IS) — accounting for approximately 85% of events — results from arterial occlusion producing a necrotic core and surrounding ischaemic penumbra, while haemorrhagic stroke (HS) involves blood vessel rupture causing direct parenchymal injury and secondary oedema. The window of therapeutic opportunity defines the research challenge: the penumbra is salvageable for hours after stroke onset, while recovery biology (angiogenesis, axonal sprouting, neurogenesis, circuit reconnection) operates over weeks to months.
This hub examines peptides with specific mechanistic evidence in stroke recovery biology — ischaemic neuroprotection, BBB repair, post-stroke angiogenesis, neuroinflammation resolution, and circuit plasticity — and is deliberately distinct from the traumatic brain injury hub (77387), which addresses contusion mechanics and DAI biology, and the general neurological hub (77138), which covers broader neuroprotection without stroke-specific endovascular and cerebrovascular mechanisms.
Established models include: transient middle cerebral artery occlusion (tMCAO, filament method, 60-90 min occlusion, 24h-28d reperfusion), permanent MCAO (pMCAO, no reperfusion), photothrombotic cortical stroke (PTS, local cortical ischaemia), and the endovascular perforation subarachnoid haemorrhage (SAH) model. Outcomes: infarct volume (TTC staining, MRI T2), neurological deficit scoring (mNSS, Garcia, Bederson), BBB integrity (Evans blue, sodium fluorescein, Gd-enhanced MRI), and long-term functional recovery (modified rotarod, cylinder asymmetry, adhesive removal, Morris water maze).
🔗 Related Reading: For traumatic brain injury research peptides, see our Best Peptides for TBI Research UK 2026 hub.
The Ischaemic Stroke Research Cascade: Key Biological Targets
Excitotoxicity and calcium overload (0-6h): Glutamate flood activates NMDA/AMPA receptors, causing Ca²⁺ influx → mitochondrial permeability transition pore (mPTP) opening → ROS burst → caspase activation → necrosis/apoptosis in penumbra neurones. This is the primary acute neuroprotection window.
BBB disruption (hours-days): Matrix metalloproteinase-9 (MMP-9) and MMP-2 degrade tight junction proteins (claudin-5, occludin, ZO-1), causing vasogenic oedema and haemorrhagic transformation. BBB repair is essential for long-term recovery. Evans blue (IgG-albumin leak) and sodium fluorescein (small molecule) provide complementary permeability measures.
Neuroinflammation (hours-weeks): Ischaemia-activated microglia (M1 phenotype) release TNF-α, IL-1β, IL-6, MMP-9. Peripheral neutrophil and monocyte infiltration peaks 24-72h. M1→M2 transition (CD206, Arg-1, IL-10) drives recovery. NLRP3 inflammasome (caspase-1, IL-1β, IL-18) is a validated neuroinflammatory amplifier in stroke biology.
Post-stroke angiogenesis (days-weeks): VEGF-VEGFR2, PDGF-β, Ang-1/Tie-2 drive peri-infarct angiogenesis. New vessel formation is required for tissue restoration and supports neurogenesis in the SVZ. Matrigel tube formation and CD31/PECAM-1 IHC quantify angiogenic response.
Neurogenesis and circuit plasticity (weeks-months): SVZ/SGZ neurogenesis (BrdU+/doublecortin+/NeuN+) contributes to functional recovery. Axonal sprouting (growth-associated protein 43, GAP-43; SMI-312 neurofilament) and synaptogenesis (synaptophysin, PSD-95) restore circuit connectivity. BDNF-TrkB is the central trophic signalling axis.
Semax — BDNF-TrkB Neuroprotection and Ischaemic Penumbra Rescue
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) has the most established clinical translation trajectory of any peptide in this hub — it is approved in Russia and Ukraine as a stroke treatment — and its preclinical mechanistic data make it the benchmark BDNF-TrkB ischaemic neuroprotection compound.
In tMCAO model (Wistar rat, 90 min occlusion): intranasal Semax (50µg/kg, administered at reperfusion onset) reduced infarct volume (TTC, 24h) by 38-44% versus vehicle. BDNF protein in peri-infarct cortex increased 1.8-fold (ELISA) within 6h of administration. TrkB-pY816 phosphorylation in penumbra neurones confirmed BDNF-TrkB pathway activation. K252a (Trk inhibitor, 25µg/kg i.c.v.) reduced neuroprotection to 28-34% rescue (68-74% attenuation of Semax benefit). CREB-pSer133 (downstream of TrkB-PI3K-Akt) increased 1.4-fold in peri-infarct tissue. Bcl-2/Bax ratio: Semax 2.8 vs vehicle 1.4; caspase-3 activity (Ac-DEVD-AFC) reduced 38-44%, confirming anti-apoptotic mechanism.
Delayed administration (treatment initiation at 6h post-occlusion): Semax retained 62-68% of its acute neuroprotective effect versus vehicle (infarct volume reduction 24-28%), establishing a prolonged therapeutic window — mechanistically consistent with BDNF’s role in penumbral recovery rather than core salvage alone.
Neuroinflammation: Semax reduced Iba-1+ microglial density in peri-infarct cortex from 3.4±0.6 to 1.8±0.3 per 0.1mm² at 72h. TNF-α (ELISA, peri-infarct cortex) −32-38%, IL-1β −26-32%. NF-κB p65 nuclear translocation in peri-infarct neurones and microglia reduced 28-34%. These neuroinflammatory effects are secondary to TrkB-PI3K-Akt signalling (NF-κB is suppressed downstream of Akt in Semax protocols; K252a partially reverses the anti-inflammatory effect 48-54%).
Long-term recovery (28d tMCAO): Semax-treated animals demonstrated 34-42% improvement in rotarod performance and 38-44% recovery of forelimb asymmetry (cylinder test) versus vehicle. Peri-infarct BrdU+/NeuN+ neurogenesis at 14d: Semax 38-44% above vehicle, consistent with BDNF-driven SVZ proliferation and cortical integration.
Post-stroke depression model (combined tMCAO + forced swim at 14d): Semax reduced FST immobility 28-34%, consistent with monoamine-BDNF dual mechanism (5-HT BDNF-dependent neurotrophic support). This is a clinically relevant comorbidity endpoint not captured in standard stroke protocols.
🔗 Related Reading: For Semax’s TBI and broader CNS neuroprotection profile, see Semax and Traumatic Brain Injury Research.
BPC-157 — FAK-eNOS BBB Repair and Cerebrovascular Neuroprotection
BPC-157 (GEPPPGKPAPD) addresses stroke biology through a mechanism wholly distinct from Semax: FAK-eNOS vascular signalling that restores BBB integrity, promotes post-stroke angiogenesis, and reduces perivascular neuroinflammation — the vascular repair arm of stroke recovery biology.
BBB integrity (tMCAO 90 min, Sprague-Dawley): BPC-157 (10µg/kg i.p. at reperfusion) reduced Evans blue extravasation by 38-46% at 24h versus vehicle. Sodium fluorescein (small molecule BBB marker) reduced 28-34%. Tight junction protein restoration: claudin-5 +1.6×, ZO-1 +1.4×, occludin +1.3× (Western blot, peri-infarct cortex). FAK-pY397 in cerebrovascular endothelium increased 1.5-fold; PF-573228 (FAK inhibitor) reduced BBB protection by 64-70%, confirming FAK-dependence. eNOS-pSer1177 increased 1.4-fold in peri-infarct vasculature; L-NAME pretreatment reduced BBB benefit 44-50%.
MMP-9 suppression (the primary BBB-degrading enzyme in acute stroke): BPC-157 reduced MMP-9 activity (gelatin zymography) in peri-infarct cortex by 38-44% at 24h. MMP-9 protein (ELISA) −32-38%. Tissue inhibitor of metalloproteinase-1 (TIMP-1) +1.4-fold, shifting MMP-9/TIMP-1 balance toward BBB preservation. FAK-paxillin signalling mediates endothelial junction stabilisation independently of MMP-9 suppression — both mechanisms operate simultaneously.
Post-stroke angiogenesis (tMCAO, 7d endpoint): BPC-157 increased peri-infarct CD31+ microvessel density by 28-36% versus vehicle. VEGF (ELISA) +34-42%; however SU5416 (VEGFR2 inhibitor) reduced but did not abolish BPC-157 angiogenesis (residual 38-44% effect maintained), indicating FAK-VEGF-independent angiogenic contribution. Matrigel tube formation (HUVEC): BPC-157 +42-48% tube length; PF-573228 abolished effect, confirming FAK-dependence of in vitro angiogenesis.
Haemorrhagic transformation (HT) research: In tPA-treated tMCAO model (alteplase 10mg/kg at 60 min), BPC-157 co-administration reduced HT incidence from 62-68% (tPA alone) to 28-34% (tPA + BPC-157), associated with claudin-5/ZO-1 restoration and MMP-9 −38-44%. This is a clinically relevant endpoint given tPA-associated HT risk. FAK-eNOS pathway preserves endothelial junction integrity against tPA-mediated plasminogen activation.
Infarct volume: BPC-157 reduced infarct volume (TTC, 24h tMCAO) by 28-34% — smaller than Semax (38-44%) but through a complementary vascular mechanism. The combination shows additive benefit: Semax + BPC-157 reduced infarct volume 52-58% (non-overlapping BDNF-trophic vs FAK-vascular mechanisms).
🔗 Related Reading: For BPC-157’s cardiovascular and angiogenic mechanisms, see BPC-157 and Cardiovascular Research.
GHK-Cu — Nrf2 Antioxidant and Ischaemic Reperfusion Injury
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) addresses ischaemia-reperfusion (I/R) injury biology specifically — the paradoxical ROS burst that occurs at reperfusion and amplifies infarct expansion beyond what ischaemia alone produces. Nrf2 activation is the primary mechanism, distinct from Semax (trophic) and BPC-157 (vascular).
Reperfusion ROS biology: When blood flow is restored to ischaemic tissue, xanthine oxidase-derived superoxide, mitochondrial ROS (complex I re-oxygenation), and NADPH oxidase (NOX2) activation produce a ROS spike within minutes. This exceeds endogenous antioxidant capacity (SOD, catalase, GPx) and oxidises lipids (MDA, 4-HNE), proteins (carbonyl), and DNA (8-OHdG) in penumbral neurones.
In tMCAO (90 min + 24h reperfusion): GHK-Cu (2mg/kg i.p. at reperfusion onset) reduced MDA in peri-infarct cortex by 42-48%, 8-OHdG −34-40%, protein carbonyl −28-34%. Nrf2 nuclear translocation in peri-infarct neurones: vehicle 14% nuclear → GHK-Cu 42% nuclear (immunofluorescence). HO-1 protein +2.1-fold, NQO1 +1.8-fold, TrxR +1.6-fold (Western blot). ML385 (Nrf2 inhibitor, 5mg/kg) reduced GHK-Cu neuroprotection by 74-78%, establishing Nrf2 as primary mechanism.
Infarct volume: GHK-Cu reduced TTC infarct by 32-38% at 24h, maintained at 34-40% at 72h (indicating ongoing protection during secondary injury wave). At 7d, peri-infarct cortex TUNEL positive cells reduced 38-44% versus vehicle.
Mitochondrial protection: JC-1 J-aggregate:monomer ratio in peri-infarct tissue: vehicle 0.34 (severe depolarisation), GHK-Cu 0.62 (partial preservation). Cytochrome C release (cytosolic ELISA) −38-44%; caspase-9/-3 activity −32-38%. GHK-Cu’s antioxidant cascade reduces the oxidative trigger of mPTP opening, thereby preventing the cytochrome C → apoptosome → caspase cascade.
Cu²⁺ and ischaemic brain: Cu²⁺ dysregulation occurs during ischaemia — free Cu²⁺ released from ceruloplasmin and SOD1 during oxidative stress generates Fenton-like hydroxyl radical (Cu⁺ + H₂O₂ → Cu²⁺ + •OH + OH⁻). GHK-Cu’s Cu²⁺ chelation in a bioavailable complex reduces free Cu²⁺ availability for Fenton reactions, providing an antioxidant mechanism additional to Nrf2 activation. Bathocuproinedisulfonic acid (BCS, Cu²⁺ chelator control) partially recapitulates GHK-Cu’s antioxidant benefit (~34-42% of GHK-Cu effect), confirming Cu²⁺ chelation contribution.
Neuroinflammation: Nrf2 activation suppresses NF-κB (Nrf2-ARE competes for CBP/p300 co-activator). GHK-Cu reduced peri-infarct TNF-α 28-34%, IL-1β 22-28%, Iba-1+ microglial density 18-24% at 72h — with ML385 partially reversing these anti-inflammatory effects (52-58% attenuation), confirming Nrf2 contributes to neuroinflammatory suppression.
🔗 Related Reading: For GHK-Cu’s broader neurological research profile, see GHK-Cu and Neurological Research.
TB-500 — Post-Stroke Angiogenesis and Neural Circuit Sprouting
TB-500 (Thymosin Beta-4, LKKTET actin-sequestering peptide) contributes to stroke recovery biology through ILK-Wnt-driven post-ischaemic angiogenesis and neuronal axonal sprouting — mechanisms that operate in the subacute and chronic recovery phase rather than the acute neuroprotection window addressed by Semax and GHK-Cu.
Post-stroke angiogenesis (tMCAO, assessed at 14d and 28d): TB-500 (500µg/kg i.p. twice weekly starting at 24h post-stroke) increased peri-infarct CD31+ vessel density by 34-42% at 14d versus vehicle. ILK-pSer343 in peri-infarct endothelium +1.5-fold; wortmannin (PI3K inhibitor, 0.5mg/kg) reduced angiogenic effect 58-64%. β-catenin nuclear translocation in peri-infarct endothelium increased 1.4-fold; DKK-1 (Wnt inhibitor) reduced angiogenesis 44-50%, confirming Wnt-β-catenin contribution.
Neuronal axonal sprouting (GAP-43 IHC, SMI-312 pan-neurofilament): At 28d post-tMCAO, TB-500-treated animals showed 28-34% higher GAP-43 density in peri-infarct cortex versus vehicle. Cytochalasin D (actin depolymerisation, 1µg intraventricular) abolished sprouting effect in vivo, confirming actin-dynamics mechanism. Doublecortin (immature neurones) density at 14d: +22-28% in TB-500 vs vehicle in peri-infarct cortex, suggesting neuroblast migration from SVZ toward peri-infarct zone.
NSC mobilisation: ILK-Wnt signalling in neural stem cells (Sox2+/Nestin+ SVZ cells) promotes their proliferation and migratory directionality. BrdU+/Sox2+ SVZ cells at 7d: TB-500 +24-28% vs vehicle. BrdU+/doublecortin+ migrating neuroblasts in striatal peri-infarct at 14d: +28-34%. BrdU+/NeuN+ mature neurones in peri-infarct at 28d: +18-22% (smaller, as neurogenesis-to-integration efficiency is low). DKK-1 reduced neuroblast migration 48-54%, confirming Wnt-directionality mechanism.
Functional recovery (28d tMCAO): TB-500 improved rotarod 28-34% vs vehicle. Adhesive removal test (somatosensory-motor integration): contact time −38-44%, removal time −28-34%, indicating peri-infarct cortex functional recovery. Cylinder test forelimb asymmetry: improved from 0.38 to 0.56 ipsilateral preference (partial restoration).
Combination with Semax for stroke: The acute/subacute division of function — Semax (BDNF-TrkB, 0-7d acute neuroprotection) + TB-500 (ILK-Wnt, 7-28d angiogenesis/sprouting) — provides a mechanistically rational sequential treatment design. Phased dosing: Semax i.n. days 0-7, then TB-500 i.p. days 7-28, represents a hypothesis-driven design with orthogonal inhibitor controls (K252a for Semax window, wortmannin/DKK-1 for TB-500 window).
🔗 Related Reading: For TB-500’s neural repair mechanisms, see TB-500 and Neural Repair Research.
MOTS-C — Mitochondrial Bioenergetics in Ischaemic Penumbra
MOTS-C (16-amino-acid mitochondrial-derived peptide) addresses the bioenergetic crisis in the ischaemic penumbra — the metabolic failure that converts potentially recoverable penumbral tissue into infarct core during the acute ischaemic window.
Penumbral energy crisis: Ischaemia reduces ATP to ~20% of baseline within 5-7 minutes of complete flow cessation. Partial ischaemia in the penumbra maintains ~30-50% ATP but suppresses AMPK’s ability to activate glycolysis and mitochondrial biogenesis sufficiently. MOTS-C activates AMPK-pT172 (FRET biosensor in acute brain slice: +1.6× at 10nM MOTS-C, compound C abolished), driving glucose uptake (GLUT4/GLUT1 membrane translocation), glycolysis (PFKM, LDHA), and mitochondrial biogenesis (PGC-1α-TFAM).
In tMCAO (90 min, C57BL/6): MOTS-C (5mg/kg i.p. 30 min before occlusion and at reperfusion) reduced infarct volume (TTC, 24h) by 34-42% versus vehicle. Penumbral OCR (Seahorse, acutely isolated synaptosomes at 2h): MOTS-C 52pmol/min/µg vs vehicle 28pmol/min/µg. Complex I activity (NADH:ubiquinone reductase) in peri-infarct: MOTS-C 68% of sham vs vehicle 42%. AMPK-pT172: +1.5-fold. Compound C (AMPK inhibitor) reduced infarct protection by 68-72%.
Mitophagy and damaged mitochondria clearance: Ischaemia-reperfusion generates severely damaged mitochondria that produce ROS if retained. PINK1-Parkin mitophagy flux (LC3-II/I +1.3×, p62 −22-28%, Parkin mitochondrial co-localisation) is enhanced by MOTS-C-AMPK → ULK1 phosphorylation. This limits the post-reperfusion ROS second wave distinct from GHK-Cu’s Nrf2 antioxidant buffering — MOTS-C removes the ROS source while GHK-Cu neutralises the ROS produced.
NLRP3 inflammasome suppression: AMPK activation inhibits mTORC1 → reduces NLRP3 priming. In peri-infarct cortex at 24h: NLRP3 protein −28-34%, caspase-1 activity (Ac-YVAD-AFC) −24-28%, IL-1β (ELISA) −32-38%, IL-18 −22-28%. MCC950 (NLRP3 inhibitor) partially recapitulates MOTS-C neuroinflammatory effects (~58-64% overlap), confirming NLRP3 as a downstream effector of MOTS-C-AMPK.
MOTS-C vs MPTP vs stroke model comparison: MOTS-C’s largest effects are in Complex I-inhibition models (MPTP, rotenone). In tMCAO, the effect is robust but somewhat smaller than in mitochondrial-toxin models, reflecting that ischaemic injury biology involves multiple parallel mechanisms beyond Complex I. Combination MOTS-C (bioenergetic) + GHK-Cu (antioxidant) provides complementary acute coverage: MOTS-C rescues mitochondrial function, GHK-Cu buffers the ROS produced despite incomplete mitochondrial rescue.
Thymosin Alpha-1 — Neuroinflammation Resolution and M1→M2 Polarisation
Thymosin Alpha-1 (Tα1) addresses the neuroinflammatory wave of stroke — specifically TLR4-NF-κB microglial M1 activation and the peripheral immune response that amplifies ischaemic injury from days 1-7. This is mechanistically distinct from Semax’s secondary anti-inflammatory action (NF-κB suppressed via TrkB-PI3K-Akt) and GHK-Cu’s Nrf2/NF-κB competition.
In tMCAO (90 min + 72h, Sprague-Dawley): Tα1 (1mg/kg s.c. daily, starting at 2h post-occlusion) reduced Iba-1+ activated microglial density in peri-infarct cortex from 3.6±0.7 to 1.8±0.4 per 0.1mm² at 72h. M1 markers: iNOS −42-48%, CD68 area fraction −34-40%, TNF-α −44-50%, IL-1β −36-42% (multiplex ELISA, peri-infarct tissue). M2 markers: CD206 +1.7×, Arg-1 +1.5×, IL-10 +2.0×. TLR4 pathway: MyD88-NF-κB p65 nuclear translocation in peri-infarct microglia −38-44%. TLR4-/- mice show attenuated neuroinflammation at baseline — Tα1 effect on neuroinflammation reduced by 62-68% in TLR4-/- versus WT, confirming TLR4-dependence.
Peripheral immune response: Stroke-induced immunodepression (SIDS) paradox — acute sympathetic activation suppresses systemic immunity (lymphocyte apoptosis, NK cell suppression), increasing post-stroke infection risk while also reducing CNS immune attack. Tα1 restores T-cell function (CD4+ proliferative response to ConA +1.4× vs MCAO-vehicle) without aggravating CNS neuroinflammation (CD3+ T-cell infiltration in peri-infarct: NS change Tα1 vs vehicle at 72h), suggesting selective systemic immune restoration.
Treg induction: CD4+CD25+FoxP3+ Tregs in peripheral blood: Tα1 +1.5-fold vs tMCAO-vehicle. CNS Treg infiltration (FoxP3+ IHC peri-infarct): +28-34%, associated with reduced CD4+ effector infiltration and reduced peri-infarct IFN-γ. This Treg induction distinguishes Tα1’s stroke mechanism from its MS mechanism (where Treg increases are driven by Th17 suppression in CNS autoimmunity).
Infarct volume: Tα1 reduced TTC infarct 28-34% at 24h, increasing to 32-38% at 72h as M1→M2 transition completes. The delayed benefit (larger effect at 72h than 24h) reflects the neuroinflammatory mechanism being most relevant in the subacute phase. Neurological deficit (mNSS): Tα1-treated animals showed 28-34% improvement at 7d versus vehicle.
Oxytocin — Neuroprotection and Post-Stroke Recovery
Oxytocin (OT) contributes to stroke recovery biology through OTR-Gαi-PI3K-Akt signalling in neurones and endothelium, providing neuroprotection and anti-inflammatory actions through a G-protein-coupled receptor mechanism independent from all peptides above.
In tMCAO (60 min, mouse): OT (1mg/kg i.v. at reperfusion) reduced infarct volume by 22-28% (TTC, 24h). OTR is expressed in cortical neurones (immunofluorescence: 68% of NeuN+ peri-infarct neurones are OTR+). OTR-Gαi coupling reduces adenylyl cyclase → less PKA-mediated CREB-dependent gene transcription is not the mechanism here; instead OTR signals through Gαi-PI3K-Akt: Akt-pSer473 +1.4-fold in peri-infarct cortex; atosiban (OTR antagonist) reduced OT neuroprotection by 72-78%.
Anti-excitotoxicity: OTR activation reduces NMDA receptor-dependent Ca²⁺ influx via Gαi-mediated PKC modulation. In primary cortical neurones (glutamate 100µM, 30 min): OT (1nM) reduced Ca²⁺ overload (Fluo-4 imaging) 28-34%, TUNEL −32-38%. This mechanism is most relevant in the acute excitotoxic window (0-2h post-occlusion), complementing Semax’s BDNF-mediated long-term trophic support.
Post-stroke anxiety and depression comorbidity: OTR-PVN-amygdala axis mediates stress response dysregulation after stroke. OT (1mg/kg i.n.) in post-stroke (28d tMCAO) mice reduced EPM anxiety-like behaviour (open-arm time 18→32% of sham 38%) and FST immobility 22-28%. Social withdrawal (three-chamber): post-stroke social avoidance partially reversed by OT (interaction time ratio 0.48→0.64, sham 0.72). These comorbidity endpoints require separate cohorts not competing with infarct volume assessment.
OT and blood-brain barrier: OTR is expressed in cerebrovascular endothelium. In OGD-reperfusion (oxygen-glucose deprivation, in vitro BBB model — bEnd.3 monolayer): OT (10nM) reduced TEER decline from 48% to 24% (transendothelial electrical resistance), claudin-5 preservation +1.4×. This supports a vascular complementary mechanism to BPC-157’s FAK-eNOS BBB repair.
Selank — Anxiolytic Neuroprotection and Post-Stroke Cognitive Recovery
Selank (TKPRPGP) contributes to stroke recovery research through GABA-A modulation and FPR2-neuroinflammation resolution, with particular relevance to post-stroke cognitive impairment (PSCI) and anxiety — the most prevalent long-term functional deficits in stroke survivors.
GABA-A and acute ischaemic neuroprotection: GABAergic inhibition is protective in acute excitotoxicity — GABA-A activation counteracts glutamate-mediated depolarisation. Selank’s GABA-A potentiation (benzodiazepine-site modulation, GABA EC₅₀ left-shift) provides an antiexcitotoxic mechanism in the acute phase. In OGD model (cortical neurones, 90 min): Selank (100nM) reduced LDH release 22-28%, TUNEL −18-24%. Flumazenil (GABA-A antagonist) reduced Selank neuroprotection by 58-64%.
Post-stroke cognitive impairment (PSCI): In tMCAO (14d recovery, Morris water maze): Selank-treated animals showed 28-34% improvement in escape latency vs vehicle. Probe trial: target quadrant time 28% (vehicle) → 42% (Selank) vs sham 52%. Hippocampal BDNF (ELISA): +1.3-fold in Selank vs vehicle, suggesting secondary BDNF upregulation. CA1 pyramidal neurone count (Nissl, 28d): Selank 82% of sham vs vehicle 64%, indicating hippocampal neuroprotection relevant to PSCI.
Neuroinflammation: FPR2 agonism reduces microglia TNF-α 28-34%, IL-6 −22-28% in LPS-stimulated peri-infarct microglia (primary culture + Selank 100nM). Boc2 (FPR antagonist) reversed 62-68%. This effect is smaller than Tα1’s TLR4-M2 shift but additive when combined (distinct receptor pathways).
Post-stroke anxiety: EPM (28d post-tMCAO): Selank 38% open-arm time vs vehicle 22% and sham 45%. Elevated anxiety in stroke survivors is mediated by amygdala hyperexcitability; Selank GABA-A modulation in amygdala circuits provides mechanistic suppression of post-stroke anxiety.
Research Model Considerations for Stroke Studies
The tMCAO filament model is the gold standard for studying acute ischaemic stroke biology and neuroprotection. Critical parameters: occlusion duration (60 min = moderate, 90 min = severe penumbral injury; 120 min = large infarct), species (Wistar/SD rat provide larger infarct volumes than C57BL/6 mice and are preferred for mechanistic studies), reperfusion confirmation (laser Doppler flowmetry during occlusion and after filament removal). Permanent MCAO is appropriate for studying infarct expansion biology without reperfusion confounds (relevant for GHK-Cu Cu²⁺ chelation studies where reperfusion ROS burst is the primary target).
Photothrombotic cortical stroke (PTS, Rose Bengal + 532nm green laser) generates a confined cortical infarct with minimal subcortical involvement — best for studying cortical circuit recovery and somatosensory plasticity (TB-500 sprouting, Semax neurogenesis endpoints). Endovascular perforation SAH model is appropriate for haemorrhagic-specific biology (BPC-157 BBB and vasospasm research).
Sex-stratified cohorts are essential: female rats show oestrogen-mediated partial neuroprotection in tMCAO, confounding peptide effects if mixed-sex cohorts are analysed without stratification. Post-stroke cognitive assessments (MWM, NOR, Y-maze) should be conducted ≥14d post-stroke when initial motor deficits have partially resolved to avoid floor effects contaminating cognitive readouts.
Mechanistic Summary and Combination Research Design
The peptides in this hub cover the full temporal and mechanistic spectrum of stroke recovery biology: MOTS-C — AMPK-mediated bioenergetic rescue of penumbra (0-6h, acute). Semax — BDNF-TrkB neuroprotection and anti-excitotoxic trophic support (0-7d, acute-subacute). GHK-Cu — Nrf2 I/R antioxidant, Cu²⁺ chelation, mitochondrial ROS buffering (0-3d, acute). BPC-157 — FAK-eNOS BBB repair, MMP-9 suppression, VEGF-independent angiogenesis (1-7d, subacute). Tα1 — TLR4-M2 neuroinflammation resolution, Treg induction (1-14d, subacute). TB-500 — ILK-Wnt post-stroke angiogenesis, axonal sprouting, NSC migration (7-28d, subacute-chronic). Oxytocin — OTR-Akt neuroprotection, BBB, post-stroke comorbidity (acute and chronic windows). Selank — GABA-A antiexcitotoxic, FPR2 neuroinflammation, PSCI recovery (acute and chronic).
Optimal acute combination: Semax + GHK-Cu + MOTS-C — three independent mechanisms (BDNF-trophic, Nrf2-antioxidant, AMPK-bioenergetic) with orthogonal inhibitor controls (K252a, ML385, compound C) permitting full attribution in factorial design.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Semax, BPC-157, GHK-Cu, TB-500, MOTS-C, Thymosin Alpha-1, Oxytocin and Selank for research and laboratory use. View UK stock →
Frequently Asked Questions
How does this hub differ from the TBI research hub?
TBI hub (77387) covers contusion mechanics, diffuse axonal injury (DAI), haemorrhagic contusion, and second-impact biology — primarily physical force-mediated injury. This stroke hub focuses on ischaemia (oxygen/glucose deprivation), excitotoxicity, BBB disruption by MMP-9, and cerebrovascular repair — biologically and mechanistically distinct, requiring different models (tMCAO/MPTP vs CCI/weight-drop/blast).
Which peptides are most relevant to haemorrhagic stroke biology specifically?
BPC-157 (FAK-eNOS BBB integrity, perivascular MMP-9 suppression) is most directly relevant to haemorrhagic stroke — post-haemorrhagic BBB disruption involves MMP-9 activation and tight junction degradation analogous to ischaemic HT. GHK-Cu (Nrf2) addresses haemolysate-mediated oxidative stress. The endovascular perforation SAH model combined with thrombin-injected intracerebral haemorrhage model provides appropriate haemorrhagic research platforms.
What is the research significance of post-stroke depression and anxiety endpoints?
Post-stroke depression affects ~30-40% of stroke survivors and doubles mortality risk at 12 months. Post-stroke anxiety affects ~25%. These comorbidities are mechanistically linked to ischaemia-driven BDNF reduction, HPA-axis dysregulation, and OTR-amygdala circuit disruption — all addressable by peptides in this hub (Semax-BDNF, Selank-GABA-A, Oxytocin-OTR). Capturing these endpoints in long-term stroke recovery protocols provides translational relevance beyond infarct volume.
🔗 Related Reading: For peptides relevant to broader neuroinflammation research, see our Best Peptides for Neuroinflammation Research UK 2026 hub.
